Clinical management and susceptibility of primary hepatic lymphoma: A cases-based retrospective study

Table 3 Characteristics of 20 immunocompromised patients and treatment

Age	Latency (years)	HIV	Autoimmune disease	Immunosuppressive agents	Subtype	Treatment
73	8	-	RA	MTX; Prednisone; Cyclophosphamide	DLBCL	Chemo + DOD
89	-	-	PBC	-	MALT	Chemo
55	11	+	-	-	HL	Surgery + Chemo
65	7	-	RA	MTX	DLBCL	Surgery + DOD
65	-	-	CTD	Azathioprine; Prednisone; Hydroxychloroquine	DLBCL	Chemo
63	10	-	RA	MTX	DLBCL	DOD
32	-	+	-	-	DLBCL	Chemo
56	7	-	RA	MTX	DLBCL	Chemo + DOD
64	2	-	RA	MTX; Infliximab	DLBCL	Chemo + DOD
67	38	-	RA	MTX; Prednisone	DLBCL	Chemo + DOD
36	10	-	ITP	MTX; Azathioprine; Steroid	DLBCL	Chemo
45	8	-	Renal transplanted	Tacrolimus; Azathioprine; Prednisone	DLBCL	-
56	-	+	-	-	Unclassified	-
64	3	-	AIHA	Corticosteroids; Rituximab; Alemtuzumab	DLBCL	Chemo
48	4	-	RA	MTX	DLBCL	DOD
27	-	+	-	-	HGBCL	-
43	-	+	-	-	ALCL	-
34	11	+	-	-	DLBCL	Chemo
62	18	-	SS	Cyclophosphamide; Prednisolone	DLBCL	Chemo + DOD
32	1	+	-	-	BL	Chemo

RA: Rheumatoid arthritis; SS: Sjogren's syndrome; PBC: Primary biliary cirrhosis; HIV: Human immunodeficiency virus; DLBCL: Diffuse large B-cell lymphoma; ALCL: Anaplastic large cell lymphoma; HL: Hodgkin lymphoma; BL: Burkitt lymphoma.